Intellipharmaceutics International Inc.

IPCI.H

CA4581733090

Pharmaceuticals

Delayed Toronto S.E. Other stock markets 12:00:00 2024-03-21 EDT			5-day change	1st Jan Change
0.08 ^CAD	-.--%		-11.11%	+6.67%

01-03	IntelliPharmaCeutics International Receives Conditional Approval For TSXV Listing	MT
2023	Intellipharmaceutics International Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2023	CI

Intellipharmaceutics International Inc. Reports Earnings Results for the First Quarter Ended February 28, 2021

April 14, 2021 at 07:51 am

Intellipharmaceutics International Inc. announced earnings results for the first quarter ended February 28, 2021. For the first quarter, the company announced total revenue - ar was USD 0 compared to USD 377,554 a year ago. Operating loss was USD 784,913 compared to USD 1.196 million a year ago. Net loss was USD 924,566 compared to USD 1.747 million a year ago. Basic loss per share from continuing operations was USD 0.04 compared to USD 0.08 a year ago.

Latest news about Intellipharmaceutics International Inc.

IntelliPharmaCeutics International Receives Conditional Approval For TSXV Listing	01-03	MT
Intellipharmaceutics International Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2023	23-10-16	CI
Intellipharmaceutics International Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2023	23-07-14	CI
IntelliPharmaCeutics International Fiscal Q2 Loss Narrows on Higher Revenue	23-07-14	MT
Intellipharmaceutics International Narrows Fiscal Q1 Loss, Revenue Rises	23-06-06	MT
Intellipharmaceutics International Inc. Brief: Recorded net loss for Q1 of US$355,738 or $0.01 per common shar	23-06-06	MT
Intellipharmaceutics International Inc. Auditor Raises 'Going Concern' Doubt	23-06-04	CI
Intellipharmaceutics International Inc. Reports Earnings Results for the First Quarter Ended February 28, 2023	23-06-04	CI
Intellipharmaceutics International Inc. Brief: Announcing Cease Trade Order	23-03-07	MT
North American Morning Briefing : More Fed -3-	23-03-03	DJ
Ontario Securities Commission Denies Intellipharmaceutics' Application for Management Cease Trade Order	23-02-08	MT
Intellipharmaceutics International Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2022	22-10-14	CI
Intellipharmaceutics International Fiscal Q3 Loss Widens	22-10-14	MT
North American Morning Briefing : All Eyes on Bank -2-	22-10-14	DJ
North American Morning Briefing : Stock Futures -2-	22-07-22	DJ
Intellipharmaceutics International Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2022	22-07-21	CI
North American Morning Briefing : Bank Earnings -2-	22-07-14	DJ
Intellipharmaceutics International Inc. Reports Earnings Results for the First Quarter Ended February 28, 2022	22-04-14	CI
IntelliPharmaCeutics International Fiscal Q1 Loss Narrows	22-04-14	MT
Earnings Flash (IPCIF) INTELLIPHARMACEUTICS INTERNATIONAL Reports Q1 Loss $-0.03	22-04-14	MT
North American Morning Briefing : Stock Futures -3-	22-02-28	DJ
Intellipharmaceutics International Inc. Auditor Raises 'Going Concern' Doubt	22-02-27	CI
Intellipharmaceutics International Inc. Reports Earnings Results for the Full Year Ended November 30, 2021	22-02-27	CI
Intellipharmaceutics International Inc. Announces Kenneth Keirstead, A Member of Board of Directors, Passed Away	22-01-13	CI
Intellipharmaceutics International Inc. Reports Earnings Results for the Third Quarter Ended August 31, 2021	21-10-15	CI

Chart Intellipharmaceutics International Inc.

Duration

Period

Chart Intellipharmaceutics International Inc.

More charts

Company Profile

Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract (GIT), diabetes and pain. Its product portfolio includes Oxycodone Hydrochloride ER, Regabatin, Dexmethylphenidate ER, Metformin ER, Venlafaxine ER, Pantoprazole ER, Quetiapine ER, Lamotrigine ER, Levetiracetam ER, Desvenlafaxine ER, Ranolazine ER, and Carvedilol ER. Its product portfolio includes both new products and controlled-release generic products. It also provides analytical services.

Sector

Pharmaceuticals

Calendar

2024-07-16 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
INTELLIPHARMACEUTICS INTERNATIONAL INC.	+6.67%	1.94M
ELI LILLY AND COMPANY	+38.51%	727B
NOVO NORDISK A/S	+33.05%	599B
JOHNSON & JOHNSON	-6.23%	354B
MERCK & CO., INC.	+18.78%	328B
ABBVIE INC.	+1.35%	277B
ASTRAZENECA PLC	+16.00%	243B
NOVARTIS AG	+8.09%	205B
ROCHE HOLDING AG	-5.77%	203B
AMGEN INC.	+6.19%	164B